Vimarsana
Biggest News Aggregation in the World

Pia Baumann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pia Baumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pia Baumann Today - Breaking & Trending Today

Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit - Vimarsana News

Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium - Vimarsana News

Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

Medivir Fostrox + Lenvima Trial Shows Improvement In Clinical Benefit In Hepatocellular Carcinoma - Vimarsana News

Medivir Fostrox + Lenvima Trial Shows Improvement In Clinical Benefit In Hepatocellular Carcinoma

Medivir AB (MVRBF.PK), a Swedish pharmaceutical company focused on cancer treatments, Tuesday announced that its ongoing phase 1b/2a study with Fostrox + Lenvima demonstrated further improvement in durable clinical benefit in advanced hepatocellular carcinoma or HCC.

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan - Vimarsana News

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday - Vimarsana News

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...